Objective To investigate the skin toxicity caused by immunotherapy in patients with non-small cell lung cancer (NSCLC), so as to provide reference for the development of targeted nursing measures. Methods A total of 110 non-small cell lung cancer patients were selected and their rashes and pruritus were followed up from the first day to the 21st day into the first immunotherapy cycle. Results In the first immunotherapy cycle, the incidence rate was 31.82% for rash, and 18.18% for pruritus, with the skin lesions being graded between level 1 and 2. The incidence rate of skin rash in patients on immunotherapy varied significantly by different genders, allergy history, TNM stages and chemotherapy history; the incidence rate of pruritus in immunotherapy patients varied significantly by allergy history, TNM stages and chemotherapy history (P<0.05, P<0.01). Conclusion The incidence rate and severity of skin toxicity is low and mild after the initial immunotherapy of NSCLC. Still the patients are in need of active intervention, especially for those who are female, have allergy or chemotherapy history, and have advanced stage cancer.